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Abstract Murine MyD88, an RNA with homology both to the 
interleukin-1 receptor signaling domain and to 'death-domains', 
is rapidly upregulated during differentiation of the myeloleuke-
mic cell line M l . We have cloned the human homologue of 
murine MyD88 and re-evaluated the murine sequence. The open 
reading frame for both species encodes a 296 amino acid protein, 
which for murine MyD88 is 53 amino acids longer than originally 
published. Human MyD88 cDNA is encoded by 5 exons, and 
maps to chromosome 3p21.3-p22 by fluorescence in situ 
hybridization (FISH). Overexpression of the death domain 
region leads to transcriptional activation of the IL-8 promoter. 
Key words: Interleukin 1 receptor; Death-domain; 
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1. Introduction 
Several proteins are known to share sequence homology 
with the type I interleukin 1 receptor (IL-1R) [1]. This homol-
ogy either extends throughout the entire open reading frame, 
as is the case in T1/ST2 [2], I L - l R r p l [3] and I L - l R A c P [4], or 
alternatively is localized to the IL-1R cytoplasmic segment 
and the comparable domain of the homologue: rsc786 [5], 
Toll [6,7], 18-Wheeler [8], and MyD88 [9]. Signal transduction 
experiments have been performed using chimeras in which the 
cytoplasmic region of either T1/ST2 or I L - l R r p l has been 
fused to the extracellular and t ransmembrane regions of the 
type-I IL-1R, demonstrating that the T1/ST2 and IL - lRrp l 
share functional as well as sequence homology with the IL-1R 
[1,3]. 
MyD88 was identified as a myeloid differentiation primary 
response gene activated in murine M l myeloid precursors fol-
lowing IL-6 induced terminal differentiation [9]. It differs from 
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the other IL-1R related proteins in that the deduced protein 
sequence predicts a soluble cytoplasmically expressed protein. 
Here we describe the cloning of the human homologue of 
MyD88 and provide a preliminary characterization of this 
IL-1R related protein. 
2. Materials and methods 
2.1. Northern blot analysis 
RNA samples (2.5 ug total RNA, or 0.5 ug poly(A)- for IMTLH) 
were electrophoresed, transferred to nylon membranes and hybridized 
as previously described [10] to antisense riboprobes made from the 
murine MyD88 cDNA. Evenness of loading was monitored by stain-
ing the filters with methylene blue prior to hybridization. 
2.2. Exon mapping 
The intron positions within the coding region of human MyD88 
were determined by PCR amplification of human genomic DNA using 
sets of sense and antisense oligonucleotides based on the cDNA se-
quence. The resultant products, where differing in size from that ob-
tained using cDNA as a template, were cloned into pBluescript (Stra-
tagene) and sequenced. 
2.3. Fluorescence in situ hybridization (FISH mapping) 
Chromosomal mapping was performed on metaphase spreads from 
normal human lymphocytes prepared according to the methods of 
Fan et al. [11]. Genomic DNA comprising the majority of the coding 
region and the 4 introns was labeled with biotin-16-dUTP (Boehringer 
Mannheim) by nick translation. Fluorescence in situ hybridization 
and detection of immunofluorescence were performed according to 
the technique of Pinkel et al. [12] with minor modifications [13]. 
The chromosome preparations were stained with both diamidino-2-
phenylindole and propidium iodide (Oncor) [11] and observed with a 
Zeiss Axiophot fluorescence microscope. Hybridization of the 1.83 kb 
genomic probe to human chromosomes revealed specific labeling on 
chromosome 3 at sub-band 3p21.3-p22. 
2.4. MyD88 expression constructs 
Mammalian expression constructs of human MyD88 were prepared 
in the plasmid pDC304, a variant of pDC302 [14], and encoded either 
the full length (residues 1-296, MAAGG...ALSLP), N-terminal half 
(residues 1-151, MAAGG...ITTLD), or C-terminal half (residues 135-
296, DSSVP...ALSLP) of MyD88. The C-terminal construct contained 
an artificially introduced start methionine. 
2.5. IL-8 promoter activation assay 
COS7 cells (1 X 105 cells per well in a 12-well tissue culture plate) 
were cotransfected with 500 ng of the appropriate test DNA and 1500 
ng of the pIL8p reporter plasmid ([1] and T.P.B., unpublished data). 
This reporter consists of nucleotides —130 to +44 of the human IL-8 
promoter fused to the IL-2Ra chain coding sequence. 2 days post-
transfection the cells were washed twice with binding medium con-
taining 5% (w/v) non-fat dry milk (5% MBM) and blocked with 2 ml 
5% MBM at 37°C for 30 min. Cells were then incubated at room 
temperature for 60-90 min with 1.5 ml/well of 5% MBM containing 
1 (ig/ml of the mouse anti-IL-2Ra antibody 2A3 [15] with gentle 
rocking. Cells were washed once with 5% MBM and incubated with 
1 ml/well of 5% MBM containing 1:100 dilution of 125I-goat anti-
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mouse IgG (Sigma) for 60 min at room temperature. Wells were 
washed four times with 5% MBM and twice with PBS. Wells were 
stripped by the addition of 0.5 M NaOH, and total counts were 
determined. 
3. Results 
Northern blot analysis using an antisense riboprobe re-
vealed that MyD88 mRNA is expressed in a variety of human 
and murine tissues albeit at varying levels (Fig. 1). Murine 
cells and tissues appear to contain a single RNA species at 
~ 2.2 kb. The apparent size of the murine mRNA is at odds 
with that previously reported [9]. In the myeloleukemic cell 
line Ml , this message appears upregulated in response to IL-6. 
Human cell lines and tissues contain two hybridizing RNA 
species ( ~ 1.6 and 3 kb). The ratio of each species varies 
between cell types. 
To isolate cDNA clones of human MyD88, we screened a X 
gtlO cDNA library prepared from the KB epidermoid carci-
noma cell line, using a single stranded DNA probe derived 
from the murine sequence. Sequence analysis of the cDNA 
clones revealed considerable homology of the partial human 
sequence with the proposed 5' UTR of the published murine 
sequence. In order to determine the correct initiating methio-
nine of the human and murine mRNAs, we performed 5' 
RACE (rapid amplification of cDNA ends) on total RNA 
isolated from human KB cells and from IL-6 stimulated mur-
ine Ml cells (Fig. 2). 
This analysis extended the open reading frame of murine 
MyD88 another 159 nucleotides (53 amino acids) upstream of 
that indicated in the original publication [9], to a methionine 
which is also conserved in human MyD88 mRNA. In the 
human sequence, an additional in-frame ATG is present in 
a proportion of the mature mRNA transcripts identified by 
the 5' RACE technique (Fig. 2); this methionine is not con-
served in murine MyD88 mRNA. It is unknown whether this 
additional ATG is utilized in vivo. 
The homologous regions of murine and human MyD88 
cDNA, beginning at the shared methionine, predict a protein 
of 296 amino acids (Fig. 3). No signal peptide or transmem-
brane regions are predicted, indicating that both proteins are 
soluble cytoplasmic proteins, with a theoretical molecular 
mass of 33.2 kDa. Human MyD88 shares 81% overall amino 
acid identity with murine MyD88, and the two proteins are of 
greatest identity (93%) in the C-terminal half of the protein. 
As previously determined from murine MyD88 [1,16,17], 
human MyD88 contains an ~150 amino acid C-terminal re-
gion which shows homology to the type I IL-1R cytoplasmic 
domain (21% identity/51% similarity). In addition, the N-ter-
minal ~ 100 amino acids contains a region that has similarity 
to the 'death-domain' of FAS and TNF p55 receptor cyto-
plasmic regions [18]. The gene encoding human MyD88 was 
mapped to chromosome 3p21.3-p22 (data not shown; see Sec-
tion 2). 
The positions of introns within the human MyD88 locus 
were mapped by PCR amplification of human genomic DNA 
using oligonucleotides derived from the human cDNA se-
quence. The coding region of human MyD88 contains 4 in-
trons (Fig. 3). The location of the second intron, near the start 
of the region homologous to the IL-1R cytoplasmic domain, 
occurs at a position similar to that of an intron in the human 
IL-1 receptor [19]. 
The effects of MyD88 over-expression were examined in 
COS7 cells transiently transfected with a mammalian expres-
sion construct containing either full-length, N-terminal (resi-
dues 1-151) or C-terminal (residues 135-296) human MyD88 
(Fig. 4). Cells were co-transfected with a reporter construct 
containing the IL-2Ra gene under the transcriptional control 
of the human IL-8 promoter [1]. This region contains the 
binding sites for the transcription factors AP-1, NFIL6 and 
N F K B , and therefore surface expression of IL-2Roc, which can 
be measured by a radiolabelled antibody directed to the re-
ceptor, is presumably proportional to the level of activation of 
some or all of these transcription factors. 
Over-expression of full length MyD88 produced a dramatic 
(12-fold) increase on the level of transcription from the IL-8 
Fig. 1. RNA analysis of MyD88 expression. RNA from different human or murine sources was probed with an antisense riboprobe from the 
murine MyD88 cDNA. The arrows represent the positions of the 28S and 18S rRNA. Human RNA sources were: Bell (B-cell line), thymocyte 
(primary cells), thymic stroma (primary cells), bone marrow (primary cells), IMTLH (bone marrow stroma cell line), and KB (epidermoid carci-
noma cell line). Murine RNA sources were: 32-D (early myeloid cell line), DA-1 (myeloid leukemic cell line), Ml (myeloleukemic cell line) pre-
pared from untreated cells, or from cells treated with 10 ng/ml human IL-6 for 24 h, BAF (pre-B-cell line), triple negative (Thyl+ CD3~ 
CD4~ CD8~ fetal liver cells), CTLL (T-cell line), spleen (total primary splenocytes). The blot shows low level non-specific hybridization of 
murine riboprobe to murine 28S rRNA. 
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Fig. 2. Analysis of mRNA ends by 5' RACE. The nucleotide sequences obtained by 5' RACE (rapid identification of cDNA ends) performed 
on 1 u,g total RNA from human KB cells, or IL-6 stimulated murine Ml cells, using a Clontech kit according to the manufacturer's protocol. 
The deduced protein sequence is also shown. The conserved ATG is assumed to encode the initiator methionine in the human mRNA. 
promoter. The same magnitude of IL-8 promoter activation 
was produced in cells over-expressing the N-terminal domain 
of MyD88. In contrast, over-expression of the C-terminal do-
main produced only a modest increase in IL-8 promoter acti-
vation (3-fold). By comparison, COS7 cells transfected with 
empty vector, and then stimulated with 10 ng/ml human IL-
loc, produce only a 7.5-fold increase in IL-8 promoter activa-
tion, by signaling through endogenous IL-1 receptors. A max-
imal response in this assay (obtained for example, by IL-1 a 
stimulation of COS cells over-expressing transfected IL-1 re-
ceptors) is typically 20-30-fold stimulation (T.P.B., unpub-
lished observations). 
4. Discussion 
We have cloned the human MyD88 transcript, and re-ex-
amined the murine MyD88 cDNA, and determined that the 
MyD88 protein is highly conserved in the two species as well 
as being 53 amino acids larger than originally reported. The 
new amino acids extend the region of homology to the death 
domains of the death-associated protein kinase (DAP-Kin), a 
member of the death-domain family typified by FAS and 
TNF p55 receptors. They do not, however, appear to code 
for a signal peptide and/or a transmembrane region. MyD88 
remains unique among proteins homologous to the IL-1 re-
ceptor in being a cytoplasmic rather than a transmembrane 
protein. 
Despite the presence of a death-domain in the N-terminal 
portion of MyD88, overexpression of full-length or partial 
MyD88 constructs in mammalian cells does not appear to 
induce apoptosis. In reporter assay experiments, however, 
over-expression of the full-length MyD88, or of the death-
domain containing N-terminal region, does induce an up-reg-
ulation of transcription from the IL-8 promoter. This upregu-
lation is specific, in that overexpression of other proteins in 
the same vector, including the C-terminal portion of MyD88, 
does not lead to an increase in IL-8 promoter driven tran-
scription (this manuscript; T.P.B. and J.S., unpublished data). 
In studies of signal transduction by the TNF p55 and FAS 
receptors, death-domains have primarily been characterized in 
terms of mediating protein-protein interactions, rather than 
for their effects on transcription. 
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Fig. 3. Amino acid sequences of human (top) and murine (bottom) MyD88, as deduced from the cDNA clones. Identities are indicated by the 
boxed and shaded regions. The human sequence shown is translated from the ATG conserved in both murine and human forms. The sequence 
contains no predicted signal peptide or transmembrane regions. The published translational start of the murine protein is indicated by an ar-
row. The positions of the 4 introns within the coding region of the human sequence are indicated by filled triangles. The number above the tri-
angle denotes the position within the codon that the intron occurs. The 'deafh-domain'-like region extends through residues 39-105; the IL-IR 
cytoplasmic domain homology extends through residues 155-296. 
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Fig. 4. Expression of human MyD88 induces transcription from the 
IL-8 promoter. COS7 cells were transfected with the indicated ex-
pression plasmids, together with a reporter plasmid containing the 
IL-8 promoter driving expression of the IL-2Ra chain cDNA. After 
48 h, the level of surface IL-2Ra was determined by the binding of 
a murine anti-IL-2Rtx antibody, followed by 125I-goat anti-mouse 
IgG serum. The 'Vector/IL-la Stim.' sample was incubated with 10 
ng/ml human IL-la for 16 h prior to performing the assay. 
MyD88 was originally identified as a differentiation marker 
in murine myeloid precursors, and alteration in the expression 
level of murine MyD88 has been used as an indicator of 
terminal differentiation in these cells [20]. However, Northern 
blot analysis indicates much more widespread expression, not 
limited to myeloid cells. While the low level expression of 
MyD88 in unstimulated Ml cells may be due to the sponta-
neous differentiation that occurs in this cell line, the presence 
of MyD88 transcripts in other lymphoid and non-lymphoid 
lines warrants caution when associating differentiation state 
with the presence or absence of MyD88 message. 
Many small cell lung carcinomas (SCLC) and non-SCLCs 
exhibit frequent allelic loss in the region of 3p21-p22 [21,22], 
indicating that this region may contain one or more tumor 
suppressor genes. Extensive investigation by many groups has 
further narrowed this region to approx. 1-2 Mb consisting of 
the region 3p21-p22 [23], 3p21.3-p22 [24], or 3p21.2-p21.3 [25]. 
The gene for human MyD88 maps to 3p21.3-p22, and is 
therefore a candidate tumor suppressor gene. However, anal-
ysis of a number of SCLC tumor lines showed that MyD88 
was not homozygously deleted, although this does not rule 
out the possibility that transcription or translation of 
MyD88 was affected in these lines (G.S. and J.R.T., unpub-
lished data). 
By sequence homology, MyD88 appears to be a member of 
both the IL-1 receptor-like family and the death-domain fam-
ily. Although the functional consequences of this homology 
have yet to be elucidated, it is tempting to speculate that the 
death domain may mediate association of MyD88 with anoth-
er protein, perhaps a transmembrane receptor, that would 
then somehow regulate the signaling activity of the IL-1 re-
ceptor-like domain. If, for example, the death domain of 
MyD88 were to associate with the death domain of the 
TNF Receptor p55, then signaling by TNF might activate 
an IL-1 like response cascade. Further work will be required 
to test these hypotheses. 
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